Fat Loss peptides

GLP-1, GIP, glucagon, and amylin agonists dominate this category — the modern weight-loss class.

Tirzepatide (Mounjaro/Zepbound) and Semaglutide (Ozempic/Wegovy) are FDA-approved. Retatrutide, Cagrilintide, and Survodutide are investigational. Effect sizes are real, side effects are real, and titration discipline is the difference between users who tolerate them and users who quit at week three.

8 entries in Fat Loss

Fat Loss

№ 003

Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

WADA bannedNot natty

Once weeklyView entry

Fat Loss

№ 008

Tirzepatide

Dual agonist (GLP-1 + GIP). FDA-approved as Mounjaro / Zepbound. Strong weight loss with cleaner side effect profile than semaglutide.

FDA ✓Not natty

Once weeklyView entry

Fat Loss

№ 009

Semaglutide

GLP-1 agonist. The original wave. Sold as Ozempic / Wegovy.

FDA ✓Not natty

Once weeklyView entry

Fat Loss

№ 016

AOD-9604

Modified fragment of HGH (residues 176-191). Targets fat metabolism without the full GH side effect profile.

WADA bannedNot natty

Once daily, fastedView entry

Fat Loss

№ 017

5-Amino-1MQ

NNMT inhibitor. Targets the enzyme that drives metabolic stagnation in obesity. Early human and animal data.

Not natty

Once or twice dailyView entry

Fat Loss

№ 022

Cagrilintide

Long-acting amylin agonist. Different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus.

Not natty

Once weeklyView entry

Fat Loss

№ 023

Survodutide

Boehringer Ingelheim dual agonist (GLP-1 + glucagon). Glucagon activation boosts metabolic rate, giving stronger fat-burn signal than GLP-1-only drugs.

Not natty

Once weeklyView entry

Fat Loss

№ 027

HGH Fragment 176-191

The fat-loss tail of the HGH molecule, isolated and used alone. Goal: trigger lipolysis without GH's water retention or insulin impact.

WADA bannedNot natty

1-2x daily, fastedView entry